Rapid dose-dependent Natural Killer (NK) cell modulation and cytokine responses following human rVSV-ZEBOV Ebolavirus vaccination

Author(s):
Pejoski, D.; Rham, C. de; Martinez-Murillo, P.; Santoro, F.; Auderset, F.; Medaglini, D.; Pozzi, G.; Vono, M.; Lambert, P.H.; Huttner, A.; Haks, M.C.; Ottenhoff, T.H.M. (0000-0003-3706-3403); Villard, J.; Siegrist, C.A.; VEBCON Consortium; VSV-EBOVAC Consortium; VSV-EBOPLUS Consortium
Published
2020
Publication type
Article / Letter to editor

Abstract

The rVSV-ZEBOV Ebolavirus vaccine confers protection within days after immunization, suggesting the contribution of innate immune responses. We report modulation of rVSV-ZEBOV vaccinee blood CD56(+) NK cell numbers, NKG2D or NKp30 surface receptor expression, Killer Immunoglobulin-like Receptor (KIR)(+) cell percentages and NK-cell-related genes on day 1 post immunization. Inverse correlations existed between the concentration of several plasma cytokines and inhibitory KIR+ CD56(dim) or cytokine-responsive CD56(bright) NK cells. Thus, NK cells may contribute to the early protective efficacy of rVSV-ZEBOV in humans.

Date issued
2020-04-14
Language
English
Publisher
NATURE PUBLISHING GROUP
Is part of
npj Vaccines (2020), No. 1
hdl
1887/3181112
doi
10.1038/s41541-020-0179-4
URL
https://www.nature.com/articles/s41541-020-0179-4